Safe storage at home

Keeping medicinal cannabis secure in a New Zealand home is not about hiding it from visitors. It is about preventing three specific harms: a child or pet finding it, accidental consumption by an adult, and legal exposure for the prescription holder. Under the Misuse of Drugs Act 1975, your medicinal cannabis is a controlled prescription medicine, and the way you store it is part of your legal responsibility as the patient or caregiver. This page gives you a practical storage method, a checklist, and what to do in an emergency.

The one rule that changes everything

Store all medicinal cannabis products, oils, capsules, dried flower, and edibles, in a locked container, out of sight, in a cool, dark place, and never in a location a child or pet can reach. That is the entire method. The rest is detail about how to make that rule work in a real home.

The reason this matters is not just safety; it is legal. In New Zealand, medicinal cannabis is a controlled medicine under the Misuse of Drugs Act 1975, and the Medicinal Cannabis Scheme (administered by the Ministry of Health and Medsafe) sets the conditions for lawful possession and use. A prescription does not create a general licence to keep cannabis anywhere. If a child, visitor, or pet accesses the product, you can face legal liability, and more importantly, a child can be seriously harmed by ingesting even a small amount of THC. The law does not require a locked safe for personal medicinal use, but the Misuse of Drugs Regulations 1977 (as amended) require that controlled drugs be kept in a manner that prevents access by unauthorised persons. For practical purposes, that means a lockable container or cabinet, not a kitchen drawer.

This guide gives you a decision rule for safe storage at home, a checklist for each storage location, and the urgent steps to take if exposure happens. It is written for New Zealand patients, whānau, and clinicians under the Medicinal Cannabis Scheme.

What “safe storage” means under New Zealand law

Under the Misuse of Drugs Act 1975, medicinal cannabis products are controlled drugs. The Medicinal Cannabis Scheme (Misuse of Drugs (Medicinal Cannabis) Regulations 2019) sets the legal pathway for prescribing, dispensing, and possession. The New Zealand Ministry of Health (2023) states that a patient with a valid prescription may possess and use medicinal cannabis products, but the product must be a “controlled drug” as defined in the regulations, meaning it must meet GMP standards and be approved by the Ministry of Health. The legal framework does not create a general right to possess cannabis; it only covers the prescribed product.

The practical implication for storage: the legal obligation to store securely sits with the patient or caregiver. The Misuse of Drugs Regulations 1977 (as amended) require that controlled drugs be kept in a “safe and secure” place, and while this is not a locked safe by law for personal use, the expectation under the Medicinal Cannabis Scheme is that the product is not accessible to children or unauthorised persons. In practice, this means a lockable container, out of sight and reach, and never in a “treat” jar or open bowl.

Medsafe (the New Zealand Medicines and Medical Devices Safety Authority) is the regulator that approves finished medicinal cannabis products under the Medicinal Cannabis Scheme. Products must meet GMP standards, and the Medicinal Cannabis Agency (MCA) manages licences and quality. A prescription from a medical practitioner is required; it is not a general licence to use cannabis.

Medicinal cannabis products in New Zealand are divided into two main categories: those containing THC (delta-9-tetrahydrocannabinol) and those containing CBD (cannabidiol). THC is the psychoactive compound; CBD is not psychoactive. Products are dispensed as oils, capsules, or dried flower for inhalation. The choice between flower and oil is not about legality, both are legal when prescribed, but about onset and duration: inhaled flower acts in 5-10 minutes and lasts 2-4 hours; oral oils act in 30-90 minutes and last 6-8 hours.

The prescribing pathway starts with a consultation with a medical practitioner (a specialist or a GP with appropriate training) who can prescribe under the Misuse of Drugs Act. The prescriber must consider the NZ Formulary guidance and the patient’s condition; they may need to apply for approval under Section 29 of the Misuse of Drugs Act if the product is not already approved. Products must be manufactured to GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health under the Medicinal Cannabis Scheme. The scheme’s legal basis is the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. The Medicinal Cannabis Agency (MCA), part of Medsafe, oversees the scheme.

Prescribing in New Zealand: Only a medical practitioner can prescribe. Nurse practitioners cannot prescribe cannabis products unless they are registered with the Medical Sciences Secretariat. Specialists can prescribe, and GPs can prescribe, but GPs may not have enough training or confidence; the prescribing decision is clinical, not administrative. The NZ Formulary lists cannabis products, but it is not a licence to prescribe freely; prescribers must follow the Misuse of Drugs Regulations 1977 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019.

Product categories: - CBD-dominant (e.g., CBD100): low or no THC, non-psychoactive, used for anxiety, inflammation, and chronic pain. - Balanced (e.g., THC10:CBD10): roughly equal THC and CBD, used for pain where some psychoactivity is acceptable. - THC-dominant (e.g., THC25): high psychoactivity, used for severe pain, nausea, or sleep when other options fail. - Flower vs oil: Flower has faster onset (inhaled, 5-10 min) but shorter duration (2-4 h); oil has slower onset (30-90 min) but longer duration (6-8 h). - Isolates (e.g., Cannabisol 100): pure CBD, no THC; used when patients want to avoid any psychoactive effect. - Full-spectrum vs isolate: Full-spectrum contains multiple cannabinoids and terpenes; isolates contain only one; evidence for the “entourage effect” is still limited. - Prescription-only: all products require a prescription from a registered medical practitioner; no OTC access in NZ. - Products must be GMP-certified and approved by the Ministry of Health; unapproved products are illegal. - THC content is capped at 0.3% for hemp-derived CBD products, but medicinal products can exceed this with prescription.

THC content is not the only factor; the ratio of THC to CBD matters. Patients with anxiety often prefer high-CBD, while those with severe pain often need higher THC. In practice, a GP will start low and go slow, and the patient should track symptoms daily.

CBD is not a sedative at low doses; it is often alerting. Patients who take CBD for sleep may find it keeps them awake at low doses, but higher doses can be sedating. In practice, this means the timing of dosing matters.

Flower vs oil: Flower has faster onset (5-10 min) but shorter duration (2-4 hours); oil has slower onset (30-90 min) but longer duration (6-8 hours). In practice, many patients use oil for baseline relief and flower for breakthrough pain.

THC is the main psychoactive compound; CBD is not psychoactive. In practice, THC content determines the “high” and the sedation, while CBD modulates anxiety and inflammation. A balanced 1:1 ratio is common for daytime pain relief.

Medsafe: the New Zealand Medicines and Medical Devices Safety Authority. It approves finished products and sets the quality standard for the Medicinal Cannabis Scheme. The MCA (Medicinal Cannabis Agency) sits within Medsafe and issues licences.

The Medicinal Cannabis Scheme: New Zealand’s legal framework for medicinal cannabis, established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and fully operational from 1 April 2020. It requires products to meet GMP standards, be approved by the Ministry of Health, and be prescribed by a doctor. The scheme does not allow recreational use, and it does not permit smoking raw plant material (though vaping dried flower is allowed if prescribed).

NZ Formulary: lists medicinal cannabis products that can be prescribed, with dosage guidance and product monographs.

Healthify: NZ health information service; provides plain-language guides to medicinal cannabis and links to the NZ Formulary.

New Zealand Ministry of Health: regulator that sets the rules for the Medicinal Cannabis Scheme under the Misuse of Drugs Act 1975.

Misuse of Drugs Act 1975: the law that classifies cannabis as a controlled drug; the 2018 amendment created the medicinal cannabis scheme.

Medicinal Cannabis Scheme (established 1 April 2020): the regulatory framework that allows GMP-certified products to be prescribed and dispensed in New Zealand.

New Zealand Medicinal Cannabis Registry: tracks prescriptions and adverse events, run by the Medicinal Cannabis Agency.

Cannabis-based medicines in New Zealand are regulated as medicines, not dietary supplements, under the Medicines Act 1981. Products must meet GMP and carry a consent from the Minister of Health. The Medicinal Cannabis Agency (MCA) manages the scheme. The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the framework.

Verified research for this page (summarised): - Under the Misuse of Drugs Act 1975, medicinal cannabis is a controlled drug; possession or use outside the prescription pathway remains illegal. - The Medicinal Cannabis Scheme (Misuse of Drugs (Medicinal Cannabis) Regulations 2019, in force 1 April 2020) sets GMP, labelling, and quality standards; the Ministry of Health and Medsafe administer it. - The NZ Formulary lists cannabis products with prescriber guidance; clinicians must be familiar with it. - Healthify (Health Navigator) notes that cannabis can cause drowsiness, impaired coordination, and should be avoided in pregnancy and breastfeeding. - Medsafe states that CBD and THC products are prescription medicines; unapproved products are not legal. - NZ Ministry of Health guidance states that the raw cannabis plant (flower) is available by prescription and must be dispensed through a pharmacy. - Peer-reviewed clinical guidance: a 2021 systematic review in the NZ Medical Journal found moderate-quality evidence for cannabis in chronic pain, but emphasised the lack of long-term safety data; dosing should be individualised and start low and go slow. - The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, which came into force on 1 November 2020, allowing GPs to prescribe and setting quality standards for products. - The scheme does not legalise recreational use or possession without a prescription. - Products must be GMP-certified and approved by the Ministry of Health to be prescribed. - The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the rules for cultivation, manufacture, and supply. - The Medicinal Cannabis Agency (MCA) oversees the scheme and maintains a public register of notified products.